ReviewAddiction (Abingdon, England)2023
Clinical management of psychostimulant withdrawal: review of the evidence.
Review in Addiction (Abingdon, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology.Journal of psychopharmacology (Oxford, England) · 2026Guideline
- Cognitive effects of methamphetamine and amphetamine withdrawal in rodents: a systematic review.Frontiers in psychology · 2026Pooled it
- Guidelines for Enhanced Recovery After Trauma and Intensive Care (ERATIC): Enhanced Recovery After Surgery (ERAS) and International Association for Trauma Surgery and Intensive Care (IATSIC) Society Recommendations: Paper 2: Postoperative and Intensive Care Recommendations.World journal of surgery · 2025Guideline
- Efficacy signals in a 12-week trial of clavulanic acid to decrease cocaine use.Drug and alcohol dependence · 2026Trial
- Approach With Caution: A Pilot Randomised Controlled Trial of Approach Bias Modification for People Undergoing Residential Treatment for Methamphetamine Use Disorder.Drug and alcohol review · 2026Trial
- Mirtazapine reduces hypothetical methamphetamine demand in humans.Drug and alcohol dependence · 2025Trial
- Factors associated with readmission to residential treatment among clients transitioned from detoxification services in Alberta, Canada.The American journal on addictions · 2026Article
- Attenuation of cue-induced heroin-seeking by the atypical antidepressant mirtazapine.Drug and alcohol dependence reports · 2026Article
- Interventions for methamphetamine use among people on methadone maintenance treatment in Vietnam: a sequential multiple assignment randomized trial (STAR-OM).The Lancet regional health. Southeast Asia · 2026Article
- Non-invasive neurostimulation techniques for the treatment of stimulant use disorders.Frontiers in psychiatry · 2026Review
- Effect of transcranial alternating current stimulation (NET Device™) on psychostimulant withdrawal severity and time course: a real-world data analysis.Frontiers in psychiatry · 2026Article
- The Diagnosis and Treatment of Stimulant-Related Emergencies.Deutsches Arzteblatt international · 2025Review
- Epigenetic Landscapes of Methamphetamine Addiction: Unravelling the Diagnostic Potential of Gene Methylation.Addiction biology · 2025Article
- Holistic Management of Adult ADHD with a History of Addiction: Emphasis on Low-Addiction-Risk Psychopharmacotherapy.Journal of clinical medicine · 2025Review
- [Challenges and chances in the management of methamphetamine-related disorders].Der Nervenarzt · 2025Review
- Clinical progress note: Management of the hospitalized patient who uses methamphetamine.Journal of hospital medicine · 2025Article
- Emerging medications and pharmacological treatment approaches for substance use disorders.Pharmacology, biochemistry, and behavior · 2025Review
- Trends, characteristics, and circumstances surrounding stimulant toxicity deaths in Ontario, Canada from 2018 to 2021.Journal of substance use and addiction treatment · 2025Article
- Optimizing Sleep Disorder Management in Hospitalized Patients: Practical Approach for Healthcare Providers.Brain and behavior · 2025Review
- COT-TT vaccine attenuates induction and expression of cocaine-induced behavioral sensitization in rats: a dose-response study.Frontiers in psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
It is estimated that a majority of people who use psychostimulants, particularly methamphetamine (MA) and cocaine, experience withdrawal upon abstinence from sustained use. This review of clinical research reports the evidence regarding biomedical and behavioral treatments for psychostimulant withdrawal symptoms. It provides a framework for clinicians and scientists to increase impact on attenuating MA and cocaine withdrawal during initial and sustained abstinence. Articles reviewed included reports of controlled clinical trials (randomized or non-randomized) reporting at least one withdrawal symptom among the outcomes or specifically studying patients in withdrawal. Potential efficacy for MA withdrawal is noted for a few medications (mirtazapine, naltrexone, bupropion) and repetitive transcranial magnetic stimulation during acute (first week), early protracted (weeks 2-4) and late protracted (> 4 weeks) withdrawal phases. Topiramate shows mixed evidence of efficacy for cocaine withdrawal. In general, there is inconsistent signal for biomedical and behavioral treatments on MA and cocaine withdrawal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.